Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban—A European comparative drug utilization study-Reference-Cited by-同舟云学术

Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban—A European comparative drug utilization study

Published:2020-11-02 Issue:3 Volume:128 Page:440-454
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin. Pharmacol. Toxicol.

Author:

Rottenkolber Marietta¹,Schmiedl Sven²³,Ibánez Luisa⁴,Sabaté Mònica⁴,Ballarín Elena⁴,Vidal Xavier⁴,Leon‐Muñoz Luz María⁵,Huerta Consuelo⁵,Martin Merino Elisa⁵,Montero Dolores⁵,Gasse Christiane⁶,Andersen Morten⁷,Aakjær Mia⁷,De Bruin Marie Louise⁸⁹,Gerlach Roman¹⁰,Tauscher Martin¹⁰,Souverein Patrick C.⁹,Ham Rianne⁹,Klungel Olaf¹¹,Gardarsdottir Helga⁹¹¹¹²,

Affiliation:

1. Diabetes Research Group Medizinische Klinik und Poliklinik IV Klinikum der Universitaet Muenchen Munich Germany

2. Philipp Klee‐Institute for Clinical Pharmacology Helios University Hospital Wuppertal Wuppertal Germany

3. Department of Clinical Pharmacology, School of Medicine, Faculty of Health Witten/Herdecke University Witten Germany

4. Fundació Institut Català de Farmacologia (FICF) Department of Clinical Pharmacology Department of Pharmacology, Toxicology and Therapeutics Hospital Universitari Vall d'HebronUniversitat Autònoma de Barcelona Barcelona Spain

5. Pharmacoepidemiology and Pharmacovigilance Division Spanish Agency for Medicines and Medical Devices (AEMPS) Madrid Spain

6. Department for Depression and Anxiety/Psychosis Research Unit Aarhus University Hospital Psychiatry Aarhus Denmark

7. Pharmacovigilance Research Centre, Department of Drug Design and Pharmacology University of Copenhagen Copenhagen Denmark

8. Copenhagen Centre of Regulatory Science (CORS), Department of Pharmacy University of Copenhagen Copenhagen Denmark

9. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences Utrecht University Utrecht The Netherlands

10. National Association of Statutory Health Insurance Physicians of Bavaria Munich Germany

11. Department of Clinical Pharmacy Division Laboratory and Pharmacy University Medical Center Utrecht Utrecht The Netherlands

12. Faculty of Pharmaceutical Sciences University of Iceland Reykjavik Iceland

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcpt.13517

Reference47 articles.

1. Dabigatran versus Warfarin in Patients with Atrial Fibrillation

2. Edoxaban versus Warfarin in Patients with Atrial Fibrillation

3. Apixaban versus Warfarin in Patients with Atrial Fibrillation

4. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

5. Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adoption of new medicines in primary care: A comparison between the uptake of new oral anticoagulants and diabetes medicines;British Journal of Clinical Pharmacology;2023-12-04

2. Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation;BMC Cardiovascular Disorders;2023-04-04

3. Update on drug interactions with non-vitamin-K-antagonist oral anticoagulants for stroke prevention in elderly patients;Expert Review of Clinical Pharmacology;2021-03-30